Skip to main content

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

| News

Biotech startup Cimeio receives 46 million Swiss francs for cell therapy

14.04.2022

Cimeio Therapeutics from Basel has received initial financing amounting to 46 million Swiss francs from Versant Ventures. The startup is developing an innovative approach for cell therapies. It aims to be a much gentler therapy for leukemia patients, for example.

The Basel-based investment group of Versant Ventures and its Ridgeline Discovery Engine have established the startup Cimeio Therapeutics AG with researchers from the University of Basel. According to a press release from the University of Basel, the cell therapy developed by Cimeio intends to make the interaction of the immune system gentler for patients with leukemia or severe autoimmune diseases such as multiple sclerosis. Versant has provided startup financing for this amounting to 46 million Swiss francs after conversion.

Cimeio focuses on an innovative approach for the transplantation of hematopoietic stem cells (HSC) and adoptive cell transfer (ACT). The project received early support through the technology transfer platform Unitectra from the universities of Basel, Bern, and Zurich, the Innovation Office of the University of Basel, and the startup accelerator BaseLaunch.

Current stem cell therapies involve the implantation of stem cells from the blood of a healthy donor. However, before this, the patient’s own stem cells must be eliminated by radiation therapy or chemotherapy, which places a huge burden on the body. After transplantation, therapy to treat any potential remaining diseased cells cannot be continued as this would also attack the new immune system.

Cimeio’s innovative cell therapy uses computer models to develop protein variants that allow donor cells to be differentiated from recipient cells. Computational biologist Dr. Rosalba Lepore states: “Our approach labels the donor immune cells without interfering with their functionality.” This means that certain cells can be eliminated in a targeted way.

Cimeio CEO Thomas Fuchs comments in a press release: “Our Shielded-Cell & Immunotherapy Pairs represent a fundamentally new approach to cellular therapy. We believe our technology platform has the potential to significantly improve HSC transplant, and will one day allow it to be given as an outpatient procedure in some circumstances.”

The startup is based at Technologiepark Basel.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.